Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Keating

Showing results (781-790 of 1,115) with videos related to

Pageof 112
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 1998
Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical responseV Gandhi, W Plunkett, C O Rodriguez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cellsV Gandhi, W Plunkett, S Weller, et al.
Blood|May 1, 1990
Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factorE H Estey, D Dixon, H M Kantarjian, et al.
Cancer|August 23, 2011
Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemiaBang-Ning Lee, Hui Gao, Evan N Cohen, et al.
Leukemia|February 25, 2012
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migrationJ Hoellenriegel, G P Coffey, U Sinha, et al.
Blood|January 20, 2011
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLLXavier C Badoux, Michael J Keating, Xuemei Wang, et al.
Stem Cells (Dayton, Ohio)|August 9, 2008
Bone marrow-derived mesenchymal stromal cells express cardiac-specific markers, retain the stromal phenotype, and do not become functional cardiomyocytes in vitroRobert A Rose, Huijie Jiang, Xinghua Wang, et al.
Cancer|August 12, 2003
Phase II study of alemtuzumab in chronic lymphoproliferative disordersAlessandra Ferrajoli, Susan M O'Brien, Jorge E Cortes, et al.
Leukemia & Lymphoma|February 22, 2018
Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemiaUri Rozovski, David M Harris, Ping Li, et al.
Blood|June 25, 2008
Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanismDunyaporn Trachootham, Hui Zhang, Wan Zhang, et al.
Pageof 112

Showing results (781-790 of 1,115) with videos related to

Sort By:
Pageof 112
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 1998
Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical responseV Gandhi, W Plunkett, C O Rodriguez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cellsV Gandhi, W Plunkett, S Weller, et al.
Blood|May 1, 1990
Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factorE H Estey, D Dixon, H M Kantarjian, et al.
Cancer|August 23, 2011
Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemiaBang-Ning Lee, Hui Gao, Evan N Cohen, et al.
Leukemia|February 25, 2012
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migrationJ Hoellenriegel, G P Coffey, U Sinha, et al.
Blood|January 20, 2011
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLLXavier C Badoux, Michael J Keating, Xuemei Wang, et al.
Stem Cells (Dayton, Ohio)|August 9, 2008
Bone marrow-derived mesenchymal stromal cells express cardiac-specific markers, retain the stromal phenotype, and do not become functional cardiomyocytes in vitroRobert A Rose, Huijie Jiang, Xinghua Wang, et al.
Cancer|August 12, 2003
Phase II study of alemtuzumab in chronic lymphoproliferative disordersAlessandra Ferrajoli, Susan M O'Brien, Jorge E Cortes, et al.
Leukemia & Lymphoma|February 22, 2018
Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemiaUri Rozovski, David M Harris, Ping Li, et al.
Blood|June 25, 2008
Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanismDunyaporn Trachootham, Hui Zhang, Wan Zhang, et al.
Pageof 112